Sort   by:  
 Page size 
UnknownPhase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4).
Not available
S-EPMC5006123 | biostudies-literature
UnknownHealth-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
Not available
S-EPMC10713185 | biostudies-literature
UnknownNivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Not available
S-EPMC8967713 | biostudies-literature
UnknownFirst-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Not available
S-EPMC8436782 | biostudies-literature
UnknownNivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.
Not available
S-EPMC12092258 | biostudies-literature
UnknownNivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Not available
S-EPMC8436591 | biostudies-literature
UnknownFirst-Line Selpercatinib or Chemotherapy and Pembrolizumab in <i>RET</i> Fusion-Positive NSCLC.
Not available
S-EPMC10698285 | biostudies-literature
UnknownCapivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Not available
S-EPMC11335038 | biostudies-literature
Sort   by:  
 Page size